STORMS microbiome reporting checklist. by Katrine Carlsen (5477300)

Subjects:

Overview of the WeARTolerance program. by Ana Beato (20489933)

Subjects:

Decreasing oxygen saturation with corresponding levels of NLR and D-dimer for understanding the interplay of inflammation. by Narendran Gopalan (110148)

iKIR score decreases protection associated with protective class II genotypes in T1D. by Laura Mora-Bitria (20477525)

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

“…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …”

PICOS criteria for the SLR. by Filip Stanicic (17808254)

“…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …”

PRISMA flow chart. by Filip Stanicic (17808254)

“…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …”

Differences in mean number of papers (top) and co-authors (bottom) depending on (1) NI membership and (2) time joined NI. by William C. Barley (8915282)

Subjects:

Regression estimates and incidence rate ratios from GLMER for number of papers (top) and coauthors (bottom). by William C. Barley (8915282)

Subjects:

This is the data set that we used to reach the conclusions drawn in the manuscript with related metadata and methods. by Farayi Kaseke (19560197)

Negative ion mode significant differential metabolites (Fold Change greater than 2 or less than 0.5). by Peng-fei Han (694841)

Positive ion mode significant differential metabolites (Fold Change greater than 2 or less than 0.5). by Peng-fei Han (694841)

Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg by David Qixiang Chen (8198265)

“…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”

Balance test results. by Le Zhu (1771669)

Subjects:

Variables. by Le Zhu (1771669)

Subjects:

Results of the parallel trend test. by Le Zhu (1771669)

Subjects: